Article de revue
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia
Typhoid vaccination is a public health priority in developing countries where young children are greatly affected by typhoid fever. Because present vaccines are not recommended for children younger than 2 years, the Novartis Vaccines Institute for Global Health developed a conjugate vaccine (Vi-CRM197) for infant immunisation. The study assesses the immunogenicity and safety of Vi-CRM197 in participants of various ages in endemic countries in south and southeast Asia.
Auteurs
Langues
- Anglais
Année de publication
2014
Journal
The Lancet Infectious Diseases
Volume
2
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Maladies
- Typhoïde
Pays
- Inde
- Pakistan
- Philippines
Mots-clés
- Introduction de nouveaux vaccins
Régions de l'OMS
- Région de la Méditerranée orientale
- Région de l'Asie du Sud-Est
- Région du Pacifique occidental